• 1
    Harper FE, Maricq HR, Turner RE, Lidman RW, Leroy EC. A prospective study of Raynaud phenomenon and early connective tissue disease: a five-year report. Am J Med 1982; 72: 8838.
  • 2
    Gerbracht DD, Steen VD, Ziegler GL, Medsger TA Jr, Rodnan GP. Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease. Arthritis Rheum 1985; 28: 8792.
  • 3
    Smith PJ, Ferro CJ, McQueen DS, Webb DJ. Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaud's disease. Br J Clin Pharmacol 1999; 47: 50713.
  • 4
    Freedman RR, Girgis R, Mayes MD. Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma. J Rheumatol 2001; 28: 11921.
  • 5
    Biondi ML, Marasini B, Bassani C, Agastoni A. Increased plasma endothelin levels in patients with Raynaud's phenomenon [letter]. N Engl J Med 1991; 324: 113940.
  • 6
    Anderson ME, Campbell F, Hollis S, Moore T, Jayson MI, Herrick AL. Non-invasive assessment of digital vascular reactivity in patients with primary Raynaud's phenomenon and systemic sclerosis. Clin Exp Rheumatol 1999; 17: 4954.
  • 7
    Khan F, Coffman JD. Enhanced cholinergic cutaneous vasodilation in Raynaud's phenomenon. Circulation 1994; 89: 11838.
  • 8
    Smith PJ, Ferro CJ, McQueen DS, Webb DJ. Functional studies in small arteries do not support a primary role for endothelin in the pathogenesis of Raynaud's disease. J Cardiovasc Pharmacol 1998; 31 Suppl 1: S473–6.
  • 9
    Flowers MA, Wang Y, Stewart RJ, Patel B, Marsden PA. Reciprocal regulation of endothelin-1 and endothelial constitutive NOS in proliferating endothelial cells. Am J Physiol 1995; 269: H198897.
  • 10
    Lekakis J, Papamichael C, Mavrikakis M, Voutsas A, Stamatelopoulos S. Effect of long-term estrogen therapy on brachial artery endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis. Am J Cardiol 1998; 82: 15557.
  • 11
    Tucker AT, Pearson RM, Cooke ED, Benjamin N. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial. Lancet 1999; 354: 16705.
  • 12
    Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 18427.
  • 13
    Cooke JP, Oka RK. Atherogenesis and the arginine hypothesis. Curr Atheroscler Rep 2001; 3: 2529.
  • 14
    Maricq HR, Weinrich MC. Diagnosis of Raynaud's phenomenon assisted by color charts. J Rheumatol 1988; 15: 4549.
  • 15
    LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 15736.
  • 16
    Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 17
    Fox RI. Sjögren's syndrome: controversies and progress. Clin Lab Med 1997; 17: 43144.
  • 18
    Bohan A, Peter JB. Polymyositis and dermatomyositis (parts 1 and 2). N Engl J Med 1975; 292: 3447, 403–7.
  • 19
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 20
    Alarcon-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease: study of 593 patients. J Rheumatol 1989; 16: 32834.
  • 21
    Mukerji B, Hardin JG. Undifferentiated, overlapping, and mixed connective tissue diseases. Am J Med Sci 1993; 305: 1149.
  • 22
    Maricq HR, Valter I, Maricq JG. An objective method to estimate the severity of Raynaud phenomenon: digital blood pressure response to cooling. Vasc Med 1998; 3: 10913.
  • 23
    Raynaud's Treatment Study Investigators. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon: results from a randomized clinical trial with 1-year follow-up. Arch Intern Med 2000; 160: 11018.
  • 24
    Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 11115.
  • 25
    Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 123541.
  • 26
    Brook RD, Brook JR, Urch B, Vincent R, Rajagopalan S, Silverman F. Inhalation of fine particulate air pollution and ozone causes acute arterial vasoconstriction in healthy adults. Circulation 2002; 105: 15346.
  • 27
    Rajagopalan S, Brook R, Mehta RH, Supiano M, Pitt B. Effect of losartan in aging-related endothelial impairment. Am J Cardiol 2002; 89: 5626.
  • 28
    Shamim-Uzzaman QA, Pfenninger D, Kehrer C, Chakrabarti A, Kacirotti N, Rubenfire M, et al. Altered cutaneous microvascular responses to reactive hyperaemia in coronary artery disease: a comparative study with conduit vessel responses. Clin Sci (Colch) 2002; 103: 26773.
  • 29
    Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899906.
  • 30
    Block JA, Sequeira W. Raynaud's phenomenon. Lancet 2001; 357: 20428.
  • 31
    Fraenkel L. Raynaud's phenomenon: epidemiology and risk factors. Curr Rheumatol Rep 2002; 4: 1238.
  • 32
    Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 1998; 158: 595600.
  • 33
    Del Bianco E, Magini B, Muscarella G, Cappugi P, Lotti T. Raynaud's phenomenon (primary or secondary to systemic sclerosis): the usefulness of laser-Doppler flowmetry in the diagnosis. Int Angiol 2001; 20: 30713.
  • 34
    Wigley FM. Raynaud's phenomenon and other features of scleroderma, including pulmonary hypertension. Curr Opin Rheumatol 1996; 8: 5618.
  • 35
    Yamane K, Kashiwagi H, Suzuki N, Miyauchi T, Yanagisawa M, Goto K, et al. Elevated plasma levels of endothelin-1 in systemic sclerosis [letter]. Arthritis Rheum 1991; 34: 2434.
  • 36
    Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease [see comments]. Circulation 1997; 95: 206874.
  • 37
    Faraci FM, Brian JE Jr, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol 1995; 269: H15227.
  • 38
    Kurose I, Wolf R, Grisham MB, Granger DN. Effects of an endogenous inhibitor of nitric oxide synthesis on postcapillary venules. Am J Physiol 1995; 268: H222431.
  • 39
    Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 30925.
  • 40
    Calver A, Collier J, Leone A, Moncada S, Vallance P. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens 1993; 7: 1934.
  • 41
    Chen JW, Hsu NW, Wu TC, Lin SJ, Chang MS. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol 2002; 90: 97482.
  • 42
    Ohnishi M, Wada A, Tsutamoto T, Fujii M, Matsumoto T, Yamamoto T, et al. Endothelin stimulates an endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, in experimental heart failure. Clin Sci (Colch) 2002; 103 Suppl 48: 241S–244S.
  • 43
    Pang CY, Yang RZ, Neligan P, Xu N, Chiu C, Zhong A, et al. Vascular effects and mechanism of action of endothelin-1 in isolated perfused pig skin. J Appl Physiol 1995; 79: 210613.
  • 44
    Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 21137.
  • 45
    Molet S, Furukawa K, Maghazechi A, Hamid Q, Giaid A. Chemokine- and cytokine-induced expression of endothelin 1 and endothelin-converting enzyme 1 in endothelial cells. J Allergy Clin Immunol 2000; 105: 3338.
  • 46
    Parissis JT, Korovesis S, Giazitzoglou E, Kalivas P, Katritsis D. Plasma profiles of peripheral monocyte-related inflammatory markers in patients with arterial hypertension: correlations with plasma endothelin-1. Int J Cardiol 2002; 83: 1321.
  • 47
    Blann AD, Herrick A, Jayson MI. Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Br J Rheumatol 1995; 34: 8149.